Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

ClinicalTrials.gov ID: NCT04328077

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04328077. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.

Study identification

NCT ID
NCT04328077
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
101 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 18, 2020 (Actual)
Primary completion
May 19, 2021 (Actual)
Completion
May 19, 2021 (Actual)
Last update posted
Aug 9, 2022

2020 – 2021

United States locations

U.S. sites
31
U.S. states
12
U.S. cities
26
Facility City State ZIP Site status
Terns Clinical Study Site 1017 Chandler Arizona 85224 —
Terns Clinical Study Site 1018 Tucson Arizona 85712 —
Terns Clinical Study Site 1024 Tucson Arizona 85712 —
Terns Clinical Study Site 1004 Coronado California 92117 —
Terns Clinical Study Site 1035 Fresno California 93720 —
Terns Clinical Study Site 1013 La Jolla California 92037 —
Terns Clinical Study Site 1016 Los Angeles California 90036 —
Terns Clinical Study Site 1008 Montclair California 91763 —
Terns Clinical Study Site 1001 Panorama City California 91402 —
Terns Clinical Study Site 1012 Gainesville Florida 32610 —
Terns Clinical Study Site 1007 Hialeah Florida 33013 —
Terns Clinical Study Site 1028 Hialeah Florida 33014 —
Terns Clinical Study Site 1009 Miami Florida 33166 —
Terns Clinical Study Site 1033 Orlando Florida 32806 —
Terns Clinical Study Site 1032 Indianapolis Indiana 46202 —
Terns Clinical Study Site 1010 Bastrop Louisiana 71220 —
Terns Clinical Study Site 1037 New Orleans Louisiana 70121 —
Terns Clinical Study Site 1023 Shreveport Louisiana 71105 —
Terns Clinical Study Site 1002 Baltimore Maryland 21202 —
Terns Clinical Study Site 1011 Boston Massachusetts 02118 —
Terns Clinical Study Site 1038 Florham Park New Jersey 07932 —
Terns Clinical Study Site 1027 Durham North Carolina 27710 —
Terns Clinical Study Site 1014 Hermitage Tennessee 37076 —
Terns Clinical Study Site 1005 Arlington Texas 76012 —
Terns Clinical Study Site 1025 Georgetown Texas 78628 —
Terns Clinical Study Site 1021 Houston Texas 77030 —
Terns Clinical Study Site 1029 Houston Texas 77030 —
Terns Clinical Study Site 1006 San Antonio Texas 78215 —
Terns Clinical Study Site 1003 San Antonio Texas 78229 —
Terns Clinical Study Site 1019 San Antonio Texas 78229 —
Terns Clinical Study Site 1022 Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04328077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 9, 2022 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.